Krystal Biotech Files 8-K
Ticker: KRYS · Form: 8-K · Filed: Dec 12, 2024 · CIK: 1711279
| Field | Detail |
|---|---|
| Company | Krystal Biotech, Inc. (KRYS) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulatory-filing
TL;DR
Krystal Biotech filed a routine 8-K on 12/12/24. No major news.
AI Summary
Krystal Biotech, Inc. filed an 8-K on December 12, 2024, to report information under Regulation FD and to file financial statements and exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this form.
Why It Matters
This 8-K filing serves as a standard disclosure for Krystal Biotech, Inc., indicating that the company is meeting its regulatory reporting obligations with the SEC.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for disclosures and exhibits, not indicating any specific new risks or material adverse events.
Key Players & Entities
- Krystal Biotech, Inc. (company) — Registrant
- December 12, 2024 (date) — Date of Report
- Pittsburgh, Pennsylvania (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Krystal Biotech, Inc.?
The primary purpose of this 8-K filing is to report information under Regulation FD and to file financial statements and exhibits.
On what date was this 8-K filed by Krystal Biotech, Inc.?
This 8-K was filed on December 12, 2024.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is Krystal Biotech, Inc.
Where are Krystal Biotech, Inc.'s principal executive offices located?
Krystal Biotech, Inc.'s principal executive offices are located at 2100 Wharton Street, Suite 701, Pittsburgh, Pennsylvania 15203.
Does this filing indicate any specific new product approvals or clinical trial results?
This filing does not contain specific details about new product approvals or clinical trial results; it is a standard disclosure for Regulation FD and financial statements/exhibits.
Filing Stats: 622 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-12-12 08:30:31
Filing Documents
- krys-20241212.htm (8-K) — 33KB
- pressreleasedateddecember1.htm (EX-99.1) — 28KB
- krysdataannouncementq420.htm (EX-99.2) — 33KB
- image_0.jpg (GRAPHIC) — 183KB
- krysdataannouncementq420001.jpg (GRAPHIC) — 67KB
- krysdataannouncementq420002.jpg (GRAPHIC) — 202KB
- krysdataannouncementq420003.jpg (GRAPHIC) — 123KB
- krysdataannouncementq420004.jpg (GRAPHIC) — 110KB
- krysdataannouncementq420005.jpg (GRAPHIC) — 126KB
- krysdataannouncementq420006.jpg (GRAPHIC) — 107KB
- krysdataannouncementq420007.jpg (GRAPHIC) — 85KB
- krysdataannouncementq420008.jpg (GRAPHIC) — 104KB
- krysdataannouncementq420009.jpg (GRAPHIC) — 72KB
- krysdataannouncementq420010.jpg (GRAPHIC) — 127KB
- krysdataannouncementq420011.jpg (GRAPHIC) — 118KB
- krysdataannouncementq420012.jpg (GRAPHIC) — 92KB
- krysdataannouncementq420013.jpg (GRAPHIC) — 119KB
- krysdataannouncementq420014.jpg (GRAPHIC) — 102KB
- krysdataannouncementq420015.jpg (GRAPHIC) — 106KB
- krysdataannouncementq420016.jpg (GRAPHIC) — 125KB
- krysdataannouncementq420017.jpg (GRAPHIC) — 105KB
- krysdataannouncementq420018.jpg (GRAPHIC) — 155KB
- krysdataannouncementq420019.jpg (GRAPHIC) — 126KB
- krysdataannouncementq420020.jpg (GRAPHIC) — 100KB
- krysdataannouncementq420021.jpg (GRAPHIC) — 72KB
- krysdataannouncementq420022.jpg (GRAPHIC) — 123KB
- krysdataannouncementq420023.jpg (GRAPHIC) — 54KB
- 0001711279-24-000062.txt ( ) — 3941KB
- krys-20241212.xsd (EX-101.SCH) — 2KB
- krys-20241212_lab.xml (EX-101.LAB) — 20KB
- krys-20241212_pre.xml (EX-101.PRE) — 11KB
- krys-20241212_htm.xml (XML) — 2KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 12, 2024, Krystal Biotech, Inc. (the "Company") issued a press release announcing an initial clinical update for its rare respiratory disease programs KB408 and KB407, including early clinical evidence of gene delivery to the lung of AATD patients and increase in lung AAT to therapeutic levels. In addition, the press release indicated that the Company would host a conference call and webcast at 8:30 a.m. ET on December 12, 2024, to discuss the interim clinical data and its KB408 and KB407 clinical development programs. For purposes of the call and webcast, the Company provided a slide presentation, which will be available on the "Investors" section of the Company's website at www.krystalbio.com. Copies of the press release and the slide presentation are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated by reference herein. The information in this Item 7.01 of this Current Report on Form 8-K and in Exhibits 99.1 and 99.2 attached hereto shall not be (i) deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, or (ii) incorporated into any registration statement or other document filed with the Securities and Exchange Commission by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated December 12, 2024 99.2 Slide Presentation dated December 2024 104 Cover Page Interactive Data file (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 12, 2024 KRYSTAL BIOTECH, INC. By: /s/ Krish S. Krishnan Name: Krish S. Krishnan Title: Chairman and Chief Executive Officer